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Abstract
Objective: The aim of this work was to investigate whether variables identified as likely to impact the experience
of constipation in other clinical settings similarly affected the experiences of constipated palliative care patients.
Background: The majority of palliative care patients with cancer are likely to be bothered by constipation
symptoms at some point in their disease trajectory. Despite this, it remains unclear as to which factors predict
more severe problems.
Methods: This study was conducted in a sample of 94 constipated palliative care patients who were asked to
voluntarily complete a series of questions regarding their demographic and other characteristics, including
whether they had chronic constipation symptoms, that is, constipation symptoms for 12 months. Other variables
included age, body mass index, sex, performance status, and regular opioids and their doses. At the same time,
they were asked to complete the Patient Assessment of Constipation Symptoms (PAC-SYM) and Patient
Assessment of Constipation Quality of Life (PAC-QOL) questionnaires.
Results: Descriptive statistics summarized baseline data. Unadjusted associations between the selected vari-
ables on PAC-SYM were examined by using bi-variate analyses. Significant variables identified on bi-variate
analyses were included in a multivariate analysis. The final results identified that only the chronicity of
constipation symptoms predicted more severe symptoms. This relationship persisted when this single variable
was retained in the final model, illustrating that PAC-SYM scores are 0.41 higher in patients with chronic
constipation compared with those without it ( p = 0.02). In contrast, regular opioid use was not identified as a
significant factor ( p = 0.56).
Discussion: This study suggests that the factor most likely to predict worse constipation symptoms was the
duration that people had experienced problems. Further, those who perceived their constipation symptoms to be
more severe had a poorer quality of life. More work is required to better define constipation risk factors and
ways to best modify a patient’s experiences.
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Introduction
Constipation symptoms are common in palliative care.Point prevalence studies indicate that at any one time
point, nearly 20% of this patient cohort will report moderate-
to-severe constipation problems.1 Further, longitudinal data
indicate that the significant majority of people will experi-
ence symptoms at some point during their palliative care
disease trajectory.2 In contrast, 21% of the general population
report having experienced constipation at some point, and
only 3% have experienced longer term chronic symptoms.3
The burden of constipation in palliative care is reiterated
by the fact that laxatives are among the most commonly
prescribed medications for this group.4 Despite the preva-
lence of this symptom, there is no consensus as how best to
diagnose constipation or tailor treatments in palliative care.
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Objective data that define whether there are predisposing
factors that worsen the severity of a palliative patient’s
constipation symptoms are lacking.
Given this gap, a secondary analysis of previously col-
lected data was conducted with the aim of investigating
whether there were any associations between people’s self-
reported current constipation symptoms and the factors
identified as potentially contributing to worse constipation in
the general population, namely: age,5 sex,5 body mass index
(BMI),6 functional status,6 regular opioids,7 and whether
experience of constipation symptoms had persisted for 12
months.3
Methods
Secondary analysis of the baseline data collected as part of a
cohort study comparing the symptom experiences of palliative
cancer patients objectively diagnosed with constipation as
measured by colon transit times and anorectal manometry
compared with usual palliative constipation management. This
study was conducted across six Australian palliative care ser-
vices over four years (Australia and New Zealand Clinical Trials
Registry [ANZCTR] trial number ACTRN12611000705987).
The larger study was approved by the participating sites’ human
ethics committees, with this secondary analysis planned as part
of the study’s protocol. All participants provided written in-
formed consent.
Participants
Only cancer inpatients and outpatients already considered
constipated by their palliative care team and taking laxatives
(regularly and as needed) were included. Other criteria for
inclusion were that people needed to be older than 18 years of
age, have an Australian-modified Karnofsky Performance
Status (AKPS)8 of ‡40 at enrolment, be willing and able to
complete the questionnaires, not currently or intending to fall
pregnant, and, in the opinion of the referring doctor, be well
enough to complete the study. Exclusion criteria included
short-term reversible constipation attributable to specific
etiologies such as hypercalcemia or chemotherapy-induced
bowel dysfunction; and a known bowel obstruction or pre-
vious bowel surgery that resulted in a reduction of the length
of the gastrointestinal tract that may have further affected gut
transit times.
Factors previously identified as likely
to affect constipation symptoms
A range of demographic and other factors previously
suggested as likely to impact the experience of constipation
in the general population were incorporated as baseline data
in the larger study. This included:
(i) Demographic factors, including age (in years); sex;
BMI; and performance status.
(ii) Whether or not regular opioids were required, with
the 24-hour dose of those participants who required
opioids summarized as the equivalent oral morphine
(EOM) dose. The EOM was calculated by using an
existing dose conversion table.9 Doses were then
stratified as low, moderate, high, or very high doses
according to pre-existing definitions.10
(iii) Chronicity of constipation symptoms as summarized
by the Rome criteria. For this work, a previously
proposed modification of the Rome III Criteria3 was
used, requiring people to have experienced two or
more symptoms for 12 months, including (1) <3
bowel actions per week; (2) straining on at least 25%
of bowel actions; (3) hard stools at least 25% of the
time; and (4) feeling of an incomplete evacuation at
least 25% of the time.3 This modified version has
been elsewhere and is only dissimilar to both Rome
III and Rome IV because of the fact that symptoms
are reported for 12 months compared with the more
accepted 3–6 months.11
Current constipation symptoms
Participants’ current self-reported constipation symptoms
were summarized with the self-reported 12-item Patient
Assessment of Constipation Symptoms (PAC-SYM).12 This
validated tool uses a 0–4 scale (0: absent to 4: worst possible)
examining abdominal and rectal symptoms, and difficulties
passing bowel actions. The final score is calculated by di-
viding the total sum of the scores by the number of the
questions answered. The lower the final figure, the less
symptomatic the person rates themselves to be. This was
accompanied by the Patient Assessment of Constipation
Quality of Life (PAC-QOL),13 which specifically examines
the impact of people’s perceptions of their constipation
symptoms on quality of life by using an identical scoring
format to the PAC-SYM.
Analysis
Data were analyzed by using STATA SE 10 statistical
software (Stata Statistical Software; StataCorp., College Sta-
tion, TX). Descriptive statistics summarized baseline data.
Unadjusted associations between the selected variables on
PAC-SYM were examined by using bi-variate analyses. Sig-
nificant variables identified on bi-variate analyses were in-
cluded in a multivariate analysis.
Results
Patient characteristics
There were 94 participants who completed some or all of
the baseline questions (Table 1). They had a mean age of 67.5
(standard deviation [SD] –15.7) years, and 58.5% (n = 55)
were men. Only 3.9% (n = 3) identified themselves as using
laxatives on an ‘‘as needed’’ basis, with 97.5% (n = 90) taking
at least one type of laxative every day. The majority of the
group was using regular opioid analgesia (n = 71), with
41.1% (n = 30) on low opioid doses (defined as less than a
daily EOM dose of 60 mg). The remainder were using either
moderate doses as defined by an EOM dose of 61–200 mg
(n = 26) or high to very high doses defined by an EOM of
201 mg to greater than 600 mg (n = 17). Of the 73 who an-
swered the chronic constipation section, more than half de-
scribed constipation symptoms for greater than 12 months.
Constipation symptoms
The mean score of the PAC-SYM and PAC-QOL of the 88
people who completed this section was 1.2 (SD –0.8; range






y0–3.43) and 1.3 (SD –0.6; range 0–2.88), respectively, sug-gesting that this group was reasonably symptomatic. This
statement is based on the fact that previous data report that
the mean PAC-SYM of a cohort of functionally constipated
patients dissatisfied with their usual treatment was 1.61 (SD
–0.69),12 with the mean PAC-QOL scores of a similar cohort
being 1.85 (SD –0.67).13
Regression analysis
A bivariate analysis was undertaken to explore the rela-
tionship between identified variables and PAC-SYM, with
the results summarized in Table 2. The only significant
unadjusted association was between the severity of self-
reported symptoms and the chronicity with which people had
been experiencing constipation symptoms. This relationship
persisted when this single variable was retained in the final
model, which shows that PAC-SYM scores are 0.41 higher in
patients with chronic constipation than in those without it
( p = 0.02) (Table 3).
None of the study variables was significantly associated
with PAC-QOL. However, PAC-SYM and PAC-QOL were
moderately correlated with a coefficient of 0.61 ( p < 0.001),
suggesting that the more symptomatically constipated pa-
tients were, the poorer their perceived quality of life was
overall.
Discussion
The aim of this work was to undertake an investigation of
whether or not factors that have been suggested as likely to














Self-reported number of types of standard laxatives used
daily




Not recorded 1 (1.1%)
Prescribed laxatives
Stimulant plus softener 40
Macrogol 22
Rectal 19























Not recorded 8 (8.5%)
For those on opioids, mean oral morphine equivalents
Low (<60 mg) 30 (41.1%)
Moderate (61–200 mg) 26 (35.6%)
High (201–600 mg) 13 (18.8%)
Very high (>600 mg) 4 (5.5%)
PAC-SYM score 1.2 (0.8)
PAC-QOL score 1.3 (0.6)
AKPS, Australian-Modified Karnofsky Performance Status; BMI,
body mass index; PAC-QOL, Patient Assessment of Constipation
Quality of Life; PAC-SYM, Patient Assessment of Constipation
Symptoms; SD, standard deviation.
Table 2. Unadjusted Associations between the
Study Variables and the Patient Assessment
of Constipation Symptoms and Patient Assessment








Age (years) 2.32 (0.06) 0.75 (0.56)
Gender 1.68 (0.20) 0.53 (0.47)
BMI 0.39 (0.76) 0.22 (0.88)




5.74 (0.02) 2.62 (0.11)
Regular opioids 0.35 (0.56) 0.19 (0.67)
Mean oral morphine equivalents 0.01 (0.98) 0.13 (0.72)
Table 3. Results Obtained from the Regression
Analyses for Patient Assessment
of Constipation Symptoms
Variable retained








0.41 (0.17) 2.40 (0.02)







contribute to the problems of constipation in the general
population affected palliative care patients’ self-reported
constipation symptoms. The main finding was that those with
more chronic problems tended to self-report worse con-
stipation symptoms. This is potentially a very important ob-
servation for a number of reasons. First, this work questions
whether usual assessments and treatments adequately palli-
ate constipation symptoms when people with pre-existing
chronic problems are referred to palliative care. Second, this
observation suggests that further work is required to more
clearly articulate whether sub-groups of constipated patients
within palliative care exist. Although more work is needed, it
seems reasonable to suggest that such sub-groupings will
include the proportion of people who have experienced
problems for many years as opposed to those who develop
problems secondary to progressive diseases and other issues
such as medications. It is important to more clearly articulate
this, as it is highly likely that the approaches used to palliate
constipation symptoms in these subgroups will be different.
However, this remains speculative and much more work is
required to more clearly define the subgroups.
Aside from chronicity of symptoms, the only other vari-
able that was close to being of statistical significance was age.
This is interesting, as, similar to chronicity of constipation
symptoms, age has also been defined as a risk factor in the
general population.5 It is not clear whether the relationship
between older age and constipation is due to changes in the
function of the colon or other factors such as frailty and/or
polypharmacy.14
Neither the use of regular opioids nor the doses at which
they were prescribed were identified as variables that affected
the severity of people’s perceptions of constipation. This
observation requires further examination, as it is in contrast to
the reported experiences of people using regular opioids for
chronic pain. In this latter cohort, it has been identified that
people regularly do not comply with their analgesic regime to
improve their experiences of constipation.15 However, whe-
ther this also occurs in palliative care is not known.16 Another
pertinent finding that requires comment is the observation
that the more severe participants’ self-reported symptoms
were, the worse the patients perceived their quality of life to
be as a result of constipation symptoms. Although this is not a
new observation,17 it does reiterate the seriousness of this
issue and reinforce the need to more clearly define factors that
contribute to constipation symptoms and how they can best
be addressed so that quality of life can be improved.
There are strengths and weaknesses of this work. A sig-
nificant strength is that this work used the modified Rome III
criteria to summarize the chronicity of problems, with this
version requiring symptoms to have been present for 12
months.3 It is likely that this duration of problems identified,
perhaps for the first time, a specific cohort of people who had
long-standing issues that probably predated their time in
palliative care. These data may have been different should the
original version of Rome III or the more recent version of the
Rome criteria (Rome IV) have been used with both these
versions, requiring people to have had problems for six
months with diagnostic criteria fulfilled for at least three
months before presentation.11
Although this study has sought to examine factors that
contribute to the severity of people’s constipation symptoms,
it is a secondary analysis of an existing dataset and additional
research is required to explore these findings further. In ad-
dition, the duration of the time that people had been pre-
scribed regular opioids was not included in the baseline data
collection, with this factor requiring attention in the future.
This is particularly when the adverse effects of prolonged
opioid therapy are considered, such as pharmacologic opioid
tolerance resulting in the need for dose escalation.18 Despite
these limitations, a significant strength of this analysis is that
it is one of the first attempts to define whether there are factors
that impact the severity of a palliative patient’s constipation
symptoms. As many of the included factors are unlikely to be
reversible, standard constipation treatments are unlikely to be
effective and alternative palliative symptom management
approaches are required.
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